BIOCON2022-10-012022-12-31 BIOCON2022-10-012022-12-31 BIOCON2022-10-012022-12-31in-bse-fin:OneOperatingExpenses01Member BIOCON2022-10-012022-12-31in-bse-fin:OneOperatingExpenses02Member BIOCON2022-10-012022-12-31in-bse-fin:FourOperatingExpenses01Member BIOCON2022-10-012022-12-31in-bse-fin:FourOperatingExpenses02Member BIOCON2022-12-31 BIOCON2022-10-012022-12-31in-bse-fin:OneReportableSegmentRevenue01Member BIOCON2022-10-012022-12-31in-bse-fin:OneReportableSegmentRevenue02Member BIOCON2022-10-012022-12-31in-bse-fin:OneReportableSegmentRevenue03Member BIOCON2022-10-012022-12-31in-bse-fin:OneReportableSegmentRevenue04Member BIOCON2022-10-012022-12-31in-bse-fin:FourReportableSegmentRevenue01Member BIOCON2022-10-012022-12-31in-bse-fin:FourReportableSegmentRevenue02Member BIOCON2022-10-012022-12-31in-bse-fin:FourReportableSegmentRevenue03Member BIOCON2022-10-012022-12-31in-bse-fin:FourReportableSegmentRevenue04Member BIOCON2022-10-012022-12-31in-bse-fin:OneReportableSegmentResults01Member BIOCON2022-10-012022-12-31in-bse-fin:OneReportableSegmentResults02Member BIOCON2022-10-012022-12-31in-bse-fin:OneReportableSegmentResults03Member BIOCON2022-10-012022-12-31in-bse-fin:OneReportableSegmentResults04Member BIOCON2022-10-012022-12-31in-bse-fin:FourReportableSegmentResults01Member BIOCON2022-10-012022-12-31in-bse-fin:FourReportableSegmentResults02Member BIOCON2022-10-012022-12-31in-bse-fin:FourReportableSegmentResults03Member BIOCON2022-10-012022-12-31in-bse-fin:FourReportableSegmentResults04Member BIOCON2022-10-012022-12-31in-bse-fin:OneReportableSegmentAssets01Member BIOCON2022-10-012022-12-31in-bse-fin:OneReportableSegmentAssets02Member BIOCON2022-10-012022-12-31in-bse-fin:OneReportableSegmentAssets03Member BIOCON2022-10-012022-12-31in-bse-fin:OneReportableSegmentAssets04Member BIOCON2022-10-012022-12-31in-bse-fin:OneReportableSegmentLiabilities01Member BIOCON2022-12-31in-bse-fin:OneReportableSegmentLiabilities01Member BIOCON2022-10-012022-12-31in-bse-fin:OneReportableSegmentLiabilities02Member BIOCON2022-12-31in-bse-fin:OneReportableSegmentLiabilities02Member BIOCON2022-10-012022-12-31in-bse-fin:OneReportableSegmentLiabilities03Member BIOCON2022-12-31in-bse-fin:OneReportableSegmentLiabilities03Member BIOCON2022-10-012022-12-31in-bse-fin:OneReportableSegmentLiabilities04Member BIOCON2022-12-31in-bse-fin:OneReportableSegmentLiabilities04Member BIOCON2022-10-012022-12-31in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member BIOCON2022-10-012022-12-31in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss02Member BIOCON2022-10-012022-12-31in-bse-fin:FourItemsThatWillNotBeReclassifiedToProfitAndLoss01Member BIOCON2022-10-012022-12-31in-bse-fin:FourItemsThatWillNotBeReclassifiedToProfitAndLoss02Member BIOCON2022-10-012022-12-31in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss01Member BIOCON2022-10-012022-12-31in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss02Member BIOCON2022-10-012022-12-31in-bse-fin:FourItemsThatWillBeReclassifiedToProfitAndLoss01Member BIOCON2022-10-012022-12-31in-bse-fin:FourItemsThatWillBeReclassifiedToProfitAndLoss02Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 532523 BIOCON NOTLISTED Biocon Limited Equity 2022-04-01 2023-03-31 2023-02-14 2023-01-06 INR Millions Third quarter 15:30:00 18:50:00 2023-02-14 2023-02-14 Not applicable Multi segment 2022-10-01 2022-12-31 Unaudited Consolidated 29411000000.00 786000000.00 30197000000.00 10736000000.00 374000000.00 -1314000000.00 5588000000.00 1203000000.00 3011000000.00 7584000000.00 27182000000.00 3015000000.00 -2714000000.00 301000000.00 -48000000.00 0.00 -48000000.00 0.00 349000000.00 0.00 0.00 0.00 -556000000.00 -207000000.00 1895000000.00 1688000000.00 -418000000.00 211000000.00 1391000000.00 297000000.00 6003000000.00 5 -0.35 -0.35 0.00 0.00 -0.35 -0.35 1. The unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2022 in respect of Biocon Limited (‘the Company’) have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meetings held on February 14, 2023. The above results have been subjected to limited review by the statutory auditors of the Company. The reports of the statutory auditors are unqualified. 2. These financial results have been prepared in accordance with Indian Accounting Standards (‘Ind AS’) prescribed under Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. 3. The consolidated financial results include the financial results of the parent company Biocon Limited and the financial results of the following subsidiaries: i. Syngene International Limited (‘Syngene’) ii. Biocon Biologics Limited (“BBL”) (formerly known as ‘Biocon Biologics India Limited’) iii. Biocon Pharma Limited (“BPL”) iv. Biocon Academy v. Biocon SA vi. Biocon SDN. BHD vii. Biocon FZ LLC viii. Biocon Biologics UK Limited (formerly known as ‘Biocon Biologics Limited’) ix. Biocon Pharma Inc. x. Biocon Biologics Healthcare Malaysia SDN. BHD (formerly known as ‘Biocon Healthcare SDN. BHD’) xi. Biocon Pharma Ireland Limited xii. Biocon Pharma UK Limited xiii. Biocon Biosphere Limited xiv. Biocon Biologics Inc. xv. Biocon Biologics Do Brasil Ltda xvi. Biocon Biologics FZ-LLC xvii. Biocon Pharma Malta Limited xviii. Biocon Pharma Malta I Limited xix. Biofusion Therapeutics Limited xx. Syngene USA Inc. xxi. Syngene Manufacturing Solutions Limited xxii. Syngene Scientific Solutions Limited xxiii. Biosimilar Collaborations Ireland Limited xxiv. Biosimilars Newco Limited Biocon Limited and its subsidiaries are collectively referred to as ‘the Group’. In addition to the above, the consolidated financial results also include the financial results in respect of Biocon India Limited Employee Welfare Trust, Biocon Limited Employees Welfare Trust, Biocon Biologics Employees Welfare Trust and Syngene International Limited Employees Welfare Trust. The Company has also accounted for its share of interest in the joint venture i.e. NeoBiocon FZ-LLC (‘JV’) and share of investment in the associates i.e. Iatrica Inc., Bicara Therapeutics Inc. (“Bicara”), under the equity method. Due to words contraints in XBRL file, full notes are not mentioned here. For full notees on financial results, please refer intimation of Board Meeting Outcome dated Feb 14, 2023. Multi segment 2022-04-01 2022-12-31 Unaudited Consolidated 74003000000.00 2210000000.00 76213000000.00 27768000000.00 1237000000.00 -4662000000.00 16117000000.00 1702000000.00 7494000000.00 18399000000.00 68055000000.00 8158000000.00 -2884000000.00 5274000000.00 1720000000.00 0.00 1720000000.00 0.00 3554000000.00 0.00 0.00 0.00 -1269000000.00 2285000000.00 1423000000.00 3708000000.00 1495000000.00 790000000.00 3262000000.00 446000000.00 6003000000.00 5 1.25 1.25 0.00 0.00 1.25 1.25 Less: Recovery of cost from co-development partners(net) -1132000000.00 Other Expenses 8716000000.00 Less: Recovery of cost from co-development partners(net) -3904000000.00 Other Expenses 22303000000.00 Biosimilars 15066000000.00 Generics 7176000000.00 Novel Biologics 0.00 Research services 7859000000.00 Biosimilars 34806000000.00 Generics 19201000000.00 Novel Biologics 0.00 Research services 21985000000.00 30101000000.00 75992000000.00 690000000.00 1989000000.00 29411000000.00 74003000000.00 Biosimilars 1021000000.00 Generics 721000000.00 Novel Biologics -374000000.00 Research services 1399000000.00 Biosimilars 2507000000.00 Generics 1896000000.00 Novel Biologics -692000000.00 Research services 3628000000.00 2767000000.00 7339000000.00 0.00 0.00 308000000.00 1. The unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2022 in respect of Biocon Limited (‘the Company’) have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meetings held on February 14, 2023. The above results have been subjected to limited review by the statutory auditors of the Company. The reports of the statutory auditors are unqualified. 2. These financial results have been prepared in accordance with Indian Accounting Standards (‘Ind AS’) prescribed under Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. 3. The consolidated financial results include the financial results of the parent company Biocon Limited and the financial results of the following subsidiaries: i. Syngene International Limited (‘Syngene’) ii. Biocon Biologics Limited (“BBL”) (formerly known as ‘Biocon Biologics India Limited’) iii. Biocon Pharma Limited (“BPL”) iv. Biocon Academy v. Biocon SA vi. Biocon SDN. BHD vii. Biocon FZ LLC viii. Biocon Biologics UK Limited (formerly known as ‘Biocon Biologics Limited’) ix. Biocon Pharma Inc. x. Biocon Biologics Healthcare Malaysia SDN. BHD (formerly known as ‘Biocon Healthcare SDN. BHD’) xi. Biocon Pharma Ireland Limited xii. Biocon Pharma UK Limited xiii. Biocon Biosphere Limited xiv. Biocon Biologics Inc. xv. Biocon Biologics Do Brasil Ltda xvi. Biocon Biologics FZ-LLC xvii. Biocon Pharma Malta Limited xviii. Biocon Pharma Malta I Limited xix. Biofusion Therapeutics Limited xx. Syngene USA Inc. xxi. Syngene Manufacturing Solutions Limited xxii. Syngene Scientific Solutions Limited xxiii. Biosimilar Collaborations Ireland Limited xxiv. Biosimilars Newco Limited Biocon Limited and its subsidiaries are collectively referred to as ‘the Group’. In addition to the above, the consolidated financial results also include the financial results in respect of Biocon India Limited Employee Welfare Trust, Biocon Limited Employees Welfare Trust, Biocon Biologics Employees Welfare Trust and Syngene International Limited Employees Welfare Trust. The Company has also accounted for its share of interest in the joint venture i.e. NeoBiocon FZ-LLC (‘JV’) and share of investment in the associates i.e. Iatrica Inc., Bicara Therapeutics Inc. (“Bicara”), under the equity method. Due to words contraints in XBRL file, full notes are not mentioned here. For full notees on financial results, please refer intimation of Board Meeting Outcome dated Feb 14, 2023. 450000000.00 2459000000.00 6889000000.00 Biosimilars 412620000000.00 Generics 53353000000.00 Novel Biologics 957000000.00 Research services 54931000000.00 521861000000.00 -3581000000.00 518280000000.00 Biosimilars 247808000000.00 Generics 19458000000.00 Novel Biologics 245000000.00 Research services 21092000000.00 288603000000.00 30984000000.00 319587000000.00 Re-measurement of defined benefit plan 24000000.00 Equity instruments through OCI -216000000.00 Re-measurement of defined benefit plan -28000000.00 Equity instruments through OCI -386000000.00 -192000000.00 -414000000.00 -4000000.00 -15000000.00 Effective portion of gains/(losses) on hedging instruments in cash flow hedges 33000000.00 Exchange difference on translation of foreign operations 2045000000.00 Effective portion of gains/(losses) on hedging instruments in cash flow hedges -1970000000.00 Exchange difference on translation of foreign operations 3198000000.00 2078000000.00 1228000000.00 -5000000.00 -594000000.00